HANA Audit Update for SSG Hannah Marder Cancer Manager UH Bristol

2014-16 data All submitted in full to HANA High completeness on all fields (UH Bristol and RUH) Some false alarms raised by HANA team as forgot not to include recurrences in staging Some fields were excluded due to technical issues, although UH Bristol had managed to upload them via a work around

Fields focussed on The fields HANA pushed for high completeness on were: Laterality Histology code from biopsy Care plan date, intent and first treatment type TNM, performance status and comorbidity index CNS present at diagnosis Procedure code and surgeon code Radiotherapy treatment target body part Chemotherapy drug type

2017 data The first ‘proper’ HANA submission will relate to patients diagnosed between 01/11/2016 and 31/10/2017. No deadline is specified We expect to submit a high degree of completeness against the key fields Separate meetings have been held with AHP teams to help with their data collection

2017 data - responsibilities UH Bristol will take responsibility for the data of patients diagnosed at UH Bristol, Weston, Yeovil, and NBT RUH will be responsible for data of patients diagnosed at RUH UH Bristol will also ensure complete treatment information for patients diagnosed at RUH but treated at UH Bristol

Important changes from DAHNO CNS contact is taken from the diagnosis page Specific boxes for recording restorative dentistry opinion and resective pathology discussion at MDT Must set the ‘careplan agreed’ box on the MDT record to ‘yes’ for the information to pull First seen date recorded separately from the usual place

DAHNO 14-16 Treatment intent vs cancer type Cancer site Curative No active treatment Non Curative Not recorded Grand Total % Curative Bones of jaw 14   4 18 78% Hypopharynx and larynx 72 1 11 85 85% Nasopharynx and sinus 34 39 87% Oral cavity excl oropharynx 121 6 128 95% Oropharynx inc tonsil 88 13 101 Salivary and parotid glands 27 28 96% 356 3 399 89% Primary only. Full MDT data (RUH and Bristol). Source – DAHNO/HANA

DAHNO 14-16 Stage at diagnosis vs cancer type Cancer site Not staged TXN0M0 T1/2N0M0 T3/4N0M0 Nodes involved Metastatic Grand Total Bones of jaw   10 8 18 Hypopharynx and larynx 2 39 22 20 85 Nasopharynx 5 6 14 12 Oral cavity 84 19 1 128 Oropharynx 7 69 101 Salivary and parotid glands 21 28 11 172 74 136 4 399 Primary only. Full MDT data (RUH and Bristol). Source – DAHNO/HANA

DAHNO 14-16 First treatment vs cancer type Cancer site Chemorad Chemo Other Pal care Surgery RT Not stated Grand Total Bones of jaw 3 14 1 18 Hypopharynx and larynx 9 5 36 30 2 85 Nasopharynx 4 23 7 39 Oral cavity 8 104 128 Oropharynx 29 54 12 101 Salivary and parotid glands 21 28 48 19 13 252 59 399 Primary only. Full MDT data (RUH and Bristol). Source – DAHNO/HANA

DAHNO 14-16 Performance status and comorbidity index vs cancer type Cancer site PS 0 PS 1 PS 2 PS 3 PS 4 Not stated Grand Total Bones of jaw 11 1 3 18 Hypopharynx and larynx 45 8 22 4 2 85 Nasopharynx 20 12 39 Oral cavity 93 128 Oropharynx 69 5 101 Salivary and parotid glands 25 28 263 21 80 10 17 399 Cancer site None Mild Moderate Severe Not stated Grand Total Bones of jaw 12 1 3 18 Hypopharynx and larynx 35 23 6 85 Nasopharynx 20 8 9 39 Oral cavity 83 27 4 11 128 Oropharynx 62 2 15 101 Salivary and parotid glands 7 28 230 79 63 399 Primary only. Full MDT data (RUH and Bristol). Source – DAHNO/HANA